Canagliflozin consistently effective for patients of different age groups with diabetic kidney disease Dr Kartikeya Kohli21 March 2023 3:45 AM GMTAustralia: Canagliflozin consistently reduced adverse kidney and cardiovascular events in patients with diabetic kidney disease independent of sex or...
Canagliflozin use tied to reduced proteinuria in diabetes patients with HF Dr Kartikeya Kohli7 March 2023 3:30 AM GMTJapan: Proteinuria regression with canagliflozin treatment in patients with T2DM (type 2 diabetes mellitus) and chronic heart failure (CHF) is...
Is supplementation of SGLT-2 inhibitor beneficial for obese women with PCOS? Medha Baranwal28 Sep 2022 4:00 PM GMTChina: Canagliflozin and metformin combination therapy yields similar results as metformin monotherapy for improving weight control,...
Vitamin D Supplementation May Offset Bone Loss Caused by canagliflozin Dr. Kamal Kant Kohli28 Jun 2022 5:30 AM GMTSGLT2 inhibitors have been shown to slow the progression of diabetes-related kidney disease and is increasingly being considered as a first-line...
All SGLT-2 inhibitors found promising for diabetes management in Indian settings: JAPI Medha Baranwal11 Jun 2022 6:00 AM GMTMaharashtra: SGLT2 Inhibitors could be considered as an add-on to all antidiabetic agents currently used for diabetes management in the Indian...
Canagliflozin does not impact risk of neuropathy events in diabetics, shows data from CREDENCE trial Medha Baranwal24 Feb 2022 3:30 AM GMTChina: A post-hoc exploratory analysis of the CREDENCE trial revealed that canagliflozin, a SGLT2 inhibitor, did not affect the risk of neuropathy...
Quality of life in heart failure patients may be improved with Canagliflozin category Dr. Nandita Mohan5 Dec 2021 6:00 AM GMTThe CHIEF- HF trial results have shown that treating heart failure (HF) patients with canagliflozin a sodium-glucose cotransporter 2 (SGLT2)...
Canagliflozin reduces hyperkalemia risk in patients with diabetes and CKD: CREDENCE trial MD Editorial Team20 Oct 2021 3:30 AM GMTAustralia: Hyperkalemia is common in people with type 2 diabetes mellitus (T2DM) and chronic kidney disease (CKD), and it is associated with the...
Canagliflozin reduces risk of hyperkalemia in diabetics with CKD: Study Dr. Shravani Dali28 Aug 2021 3:30 AM GMTThe use of canagliflozin reduces the risk of hyperkalaemia in people with type-2 diabetes mellitus (T2DM) and chronic kidney disease (CKD) without...
Canagliflozin has no substantial effect on serum potassium levels: CANVAS program Dr. Shravani Dali18 Aug 2021 3:30 AM GMTCanagliflozin does not have a significant effect on serum potassium levels, suggests a Canagliflozin cardiovascular Assessment Study (CANVAS)...
Canagliflozin use does not significantly reduce MI risk in diabetics: Study Medha Baranwal11 Jun 2021 3:30 AM GMTAustralia: The use of SGLT2 inhibitor canagliflozin does not significantly reduce the risk of myocardial infarction (MI) in the population of CANVAS...
Health Minister discusses side-effects of SGLT-2 inhibitors in the parliament Meghna A Singhania8 Feb 2021 10:40 AM GMTNew Delhi: With the rising incidence of diabetes in the country, SGLT-2 inhibitors have emerged as one of the preferred modality of treatment....
